Study of popular anemia drug supports new guidelines for its use in dialysis patients

A new study helps dispel mounting confusion over the safety of blockbuster anemia drugs - erythropoiesis-stimulating agents - for people with kidney disease requiring dialysis, as federal regulators prepare to decide whether to impose additional restrictions on their use.

Read the whole article on Physorg

More from Physorg